

PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND
DISPLAYED ON PHAGE

This invention relates to the isolation of antibody molecules directed against self antigens, e.g. human 5 antibodies directed against human self antigens. Phage display technology for selection of antibody molecules was described in WO92/01047, PCT/GB92/00883, PCT/GB92/01755 and GB9206372.6. The applicants have realised that antibodies directed against self antigens 10 can be isolated using phage display technology.

Human antiself antibodies are of particular value for in vivo therapeutic and diagnostic purposes, since they avoid the problems arising from the antigenicity of foreign, e.g. mouse antibodies. The most useful human 15 antibodies for therapy are those directed against cell surface molecules, such as receptors, adhesins and integrins, and those directed against circulating biological effector molecules, such as hormones, growth factors and cytokines. It has been extremely difficult to 20 obtain human antibodies against such self antigens. This invention provides a powerful way of obtaining such antibodies.

It is a demanding task to isolate an antibody fragment with specificity against self antigen. Animals 25 do not normally produce antibodies to self antigens, a phenomenon called tolerance (G.J.Nossal Science 245 147-153, 1989). Autoimmune diseases may result from a breakdown in tolerance. In general, vaccination with a self antigen does not result in production of circulating 30 antibodies. It is therefore difficult to raise antibodies to self antigens, particularly in humans. It is possible to raise antibodies that recognise human antigens in an animal such as a mouse, especially if the human antigen is not too closely related to any 35 equivalent in the animal. If a human antibody is then required it is necessary to 'humanise' the antibody, e.g. by CDR grafting (patent GB2188638B).

40 Phage antibody technology as described in (WO92/01047) offers the ability to isolate such human antibodies directly. In this application, we demonstrate

for the first time that antibodies against self-antigens can be isolated from phage libraries derived from, for example, nonimmunised sources and from libraries prepared by synthetic recombination of V-gene sequences, 5 preferably recombination of VH with, DH and JH, and VL with JL sequences. These antibodies are specific for their antigen. This application shows that single libraries derived in this manner can act as a source of both foreign and self antigens and opens up the prospect 10 of a large, universal library to isolate antibodies to any antigen.

It was disclosed in patent application WO92/01047 that antibody fragments can be displayed on the surface of bacteriophage and that they will bind antigen. 15 Antibody fragments can be directly selected using this characteristic. This ability to isolate antibody fragments (Fab, Fv, scFv and VH) using their display on the surface of filamentous bacteriophage has opened up the prospect of the isolation of antibody specificities 20 (i.e. antibodies directed against a particular antigen) that were difficult or impossible to isolate previously. In particular WO92/01047 demonstrates that antibody specificities can be isolated from a human who has not been specifically immunised ('unimmunised'), even 25 specificities for antigens such as 2-phenyl-5-oxazolone to which humans will not normally be exposed.

In embodiments of this invention, natural or synthetic antibody repertoires derived from a species of mammal, such as human, mouse, rat, sheep, pig, goat, 30 horse or other, are displayed on the surface of a replicable genetic display package (rgdp) and the binding specificity for self is selected by binding to self antigen. In this process, the V gene repertoires are derived from V genes rearranged in vitro or in vivo and 35 or by mutation of (a) rearranged V gene(s). A key feature of the V gene repertoires is that they are extremely diverse in sequence, usually in excess of 10^6 different members. Indeed it is possible that a sufficiently large

library may provide a source of specificities directed against any self antigen. The V-gene repertoires are cloned into the rgdp (for example a filamentous phage vector) such that antibody repertoires are displayed on the surface of the rgdp. The rgdps encoding rare antibody specificities binding to antiself, may be selected by virtue of binding to the self antigen. The antibody repertoires may be cloned in a single replicon or a dual replicon format as described in WO92/01047 and

10 PCT/GB92/00883.

The V genes may be cloned into the genetic material of the rgdp, and expressed as single domains, for example single heavy chain variable domains, so called single domain ligands or "dAbs" (see WO90/01544), or as

15 associated antibody heavy and light chain variable domains.

The two domains could be displayed as separate polypeptide chains (linked as in Fab fragments through non-covalent association of domains and/or disulphide bonds), or as part of the same chain (single chain Fv fragments where the two domains are contained within the same polypeptide chain).

20 In WO92/01047 and examples 1 to 8 of this application we have used fusion of antibody fragments to gene 3 protein of filamentous bacteriophage for display and selection of antibody fragments. An alternative approach would be to fuse antibody fragments to gene 8 protein or other surface molecules of filamentous bacteriophage.

25 Isolation of human antibodies directed against human antigens is a demanding task. There are only a limited number of human antigens against which circulating human antibodies are naturally found. Antibodies are present directed against non-self antigens of human origin.

30 Antibodies directed against human blood group B have been isolated from a phage display library prepared from subjects of blood group O (J.D. Marks et al, J. Mol. Biol. 222 581-597, 1991), which recognise the blood group

B antigen as foreign.

This invention is concerned with a general method for the isolation of antibodies directed against self antigens which are specific for the antigen concerned.

5 Many patients show significant concentrations of circulating autoantibodies. It is estimated that 10 to 30% of B lymphocytes in normal, healthy individuals are engaged in making autoantibodies (I.R. Cohen and A. Cooke Immunol. Today 7 363-364, 1986). However, the 'natural autoantibodies' produced do not lend themselves to therapeutic use as they are often IgM, low affinity and polyreactive (P. Casali and A.L. Notkins Ann. Rev. Immunol. 7 515-531, 1989; S. Avrameas Immunol. Today 12 154-159). An immune response against self can arise in 10 autoimmune disease or after infections and a few 15 monoclonal antibodies directed against self antigens have been isolated from patients with autoimmune disease (K. James & G.T. Bell J. Immunol. Methods 100 5-40, 1987). These autoantibodies are frequently specific, but may 20 bind to only a limited range of epitopes on the antigen (M. Bouanani et al Arthritis Rheum. 34 1585-1593, 1991).

The preparation of V gene libraries derived from the mRNA of plasma cells secreting IgG (or IgM) antibody may thus lead to the isolation of antibody fragments derived 25 from autoantibodies. For instance, anti-self antibodies might be isolated from patients with autoimmune diseases, for example anti-acetylcholine receptor antibodies would be expected to be isolated from antibody repertoires made from the IgG mRNA of myasthenia gravis patients. For 30 example, an antibody fragment specific for human thyroid peroxidase has been isolated from a bacteriophage lambda library from a patient with thyroid autoimmune disease (S. Portolano et al Biochem. Biophys. Res. Commun. 179 372-377, 1991). This however required extensive 35 screening of 200,000 plaques to obtain one clone. In addition, this library was derived from thyroid tissue, a procedure not readily applicable in most instances.

In contrast, the power of selection available using

the phage system, demonstrated in WO92/01047 allows the ready isolation of autoantibodies from the IgM mRNA of peripheral blood lymphocytes of a donor without disease. We show in example 2 that antibodies binding to human

5 thyroglobulin (which can be found in the sera of people with or without symptomatic autoimmune disease), can be isolated from phage repertoires prepared from unimmunised humans. One would not expect necessarily to be able to obtain antibodies to human thyroglobulin by immunising a

10 human with human thyroglobulin, notwithstanding the presence of thyroglobulin autoantibodies in many people. Autoantibodies against thyroglobulin in normal sera have been reported often to have a high degree of polyreactivity (S. Avrameas, 1991 *supra*). In contrast,

15 those which are isolated using a method according to the present invention involving phage antibody technology, see example 2 for instance, are specific for thyroglobulin.

In this application, we also demonstrate that even

20 antibodies against human tumour necrosis factor- α can be isolated as described in example 1 from the same library as the antibodies directed against thyroglobulin. Many self antigens do not have detectable associated

25 circulating autoantibodies. Further, example 3 shows the isolation of antibodies against the self antigens mucin, carcinoembryonic antigen (CEA) and CD4, antibodies to which have not been reported in normal sera. Moreover, these antibodies are specific, whereas there is often a high degree of polyreactivity in natural autoantibodies

30 which can sometimes be found. The vast majority of self antigens do not have detectable associated circulating autoantibodies. Thus the isolation of antiself

35 antibodies as described in this invention opens the prospect of the direct isolation of human antibodies binding to human antigens for a number of purposes such as antibodies which bind to circulating hormones to block, modify or potentiate their action or antibodies that bind to cell surface antigen for imaging or killing

for example of cancer cells.

The origin of the V genes that contribute to anti-self antibodies isolated from phage display libraries is not clear. Tolerance to self antigens by the immune system (preventing the generation of antibodies directed against them) is mediated by either clonal deletion or functional inactivation (anergy) of self-reactive B lymphocytes (D.A.Nemazee & K.Burki Nature 337 562-566, 1989; C.C.Goodnow et al Nature 334 676-682, 1988; S.B.Hartley et al Nature 353 765-769, 1991;

D.M.Russell et al Nature 354 308-311, 1991). In either case little circulating anti-self antibody is detectable for most antigens. However, in the case of anergy, functionally inactivated self-reactive cells from the B cell lineage persist in peripheral lymphoid organs leading to B cells in circulation. These rare lymphocytes with anti-self specificity may provide heavy or light chain partners (or even both) for phage antibodies with anti-self specificities. Alternatively,

such anti-self specificities may arise from the combination in the library of a VH domain with a VL domain to give a specificity that is normally deleted if it occurs in nature. For this reason, combinatorial libraries and 'chain-shuffled' libraries such as described in patent applications WO92/01047 may be a particularly rich source of anti-self antibodies. A selection procedure of great power, such as that provided by phage antibodies, is required to obtain such rare anti-self antibodies.

The degree of somatic mutation observed in antiself antibody fragments isolated by phage technology in this application indicates that some have germ line sequences and have therefore arisen from virgin B cells. Other antibodies isolated by phage antibody technology in this application show somatic hypermutation indicating that the V genes have been stimulated by antigen, either a foreign cross reactive antigen or other foreign antigens. In both cases the antibody fragments isolated using phage

I 2
PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/67, 15/11, 1/11 C12N 5/10		A1	(11) International Publication Number: WO 91/09955 (43) International Publication Date: 11 July 1991 (11.07.9)
(21) International Application Number: PCT/US90/07642 (22) International Filing Date: 21 December 1990 (21.12.90) (30) Priority data: 454,783 22 December 1989 (22.12.89) US		(71)(72) Applicant and Inventor: CHAPPEL, Scott, C. [US/US 990 Centre Street, Unit #2, Jamaica Plain, MA 02130 (US). (74) Agent: BROWDY, Roger, L.; Browdy and Neimark, 41 Seventh Street, Ste. 300, N.W., Washington, DC 20001 (US). (81) Designated States: AT (European patent), AU, BB, B (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent) CH (European patent), CM (OAPI patent), DE (Eu- ropean patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), G (European patent), GR (European patent), HU, IT (Eu- ropean patent), JP, KP, KR, LK, LU (European patent) MC, MG, ML (OAPI patent), MR (OAPI patent), MV NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TR (OAPI patent), US.	
(60) Parent Application or Grant (63) Related by Continuation US Filed on 22 December 1989 (22.12.89)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): APPLIED RESEARCH SYSTEMS, ARS HOLDING MV [NL/NL]; Post Office Box 3889, Curacao (AN).			

(54) Title: ENDOGENOUS GENE EXPRESSION MODIFICATION WITH REGULATORY ELEMENT

HOMOLOGOUS RECOMBINATION CONSTRUCT FOR RAT
TSH BETA



(57) Abstract

Normally transcriptionally silent genes in a cell line or microorganism may be activated for expression by inserting a DNA regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell or which is promiscuous, the regulatory element being inserted so as to be operatively linked with the normally silent gene in question. The insertion is accomplished by means of homologous recombination by creating a DNA construct including a segment having a DNA segment of the normally silent gene (targeting DNA) and the DNA regulatory element to induce gene transcription. The technique is also used to modify the expression characteristics of any endogenous gene of a given cell line or microorganism.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9007642

SA 44095

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 18/04/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A- 8909256	05-10-89	AU-A-	3431689	16-10-89
		EP-A-	0338690	25-10-89
EP-A- 0278659	17-08-88	JP-A-	63276492	14-11-88
		ZA-A-	8800319	12-08-88
WO-A- 8805077	14-07-88	None		

-1-

Endogenous gene expression modification with regulatory element.

5

FIELD OF INVENTION

The present invention relates to a process for the modification of the expression characteristics of a gene which is naturally present within the genome of a stable cell line or cloned microorganism. In the preferred 10 embodiment, the present invention relates to a process for the activation and expression of a gene that is present within a stable cell line and normally transcriptionally silent or inert. As a result, the protein product of that gene is expressed. This phenomenon occurs without 15 transfecting the cell with the DNA that encodes the product. Rather, the resident gene coding for the desired product is identified within a cell and activated by inserting an appropriate regulatory segment through a technique called homologous recombination. Positive and/or 20 negative selectable markers can also be inserted to aid in selection of the cells in which proper homologous recombination events have occurred. As an additional embodiment, a specified gene can be amplified for enhanced expression rates, whether that gene is normally 25 transcriptionally silent and has been activated by means of the present invention, or endogenously expresses product.

BACKGROUND OF THE INVENTION

It is well known that each cell within an 30 organism contains the genetic information that encodes all of the proteins found within that organism. However, only a very small percentage of the genes present within a given cell type is actually transcribed. The intracellular mechanisms that regulate the array of genes to be 35 transcribed are now understood. Cell specific proteins present within the nucleus interact with DNA regulatory

- 2 -

segments that are linked with particular genes. This interaction of nuclear proteins with DNA regulatory sequences is required for gene transcription. This results in mRNA biosynthesis and ultimate expression of the encoded 5 protein (Mitchell and Tjian, Science, 245:371, 1989).

These DNA regulatory segments or elements for each gene lie upstream from and, in some cases, within or even downstream of the coding regions. Through an interaction with cell specific nuclear proteins, DNA 10 regulatory segments affect the ability of RNA polymerase, the rate limiting enzyme in protein expression, to gain access to the body of the gene and synthesize a mRNA transcript. Thus, these DNA segments and the resident 15 nuclear proteins play a critical role in the regulation of expression of specific genes (Johnson and McKnight, Ann. Rev. Biochem., 58:799, 1989).

The DNA regulatory segments are binding sites for the nuclear proteins. These nuclear proteins attach to the DNA helix and apparently alter its structure to make the 20 desired gene available for RNA polymerase recognition, which facilitates gene transcription. The expression of these cell specific regulatory proteins determines which genes will be transcribed within a cell and the rate at which this expression will occur. As an example of the 25 specificity of this system, pituitary cells but not liver cells express pituitary proteins, even though the genes for the pituitary proteins are present within all liver cells. Nuclei of the liver cells do not contain the specific DNA binding proteins which interact with the elements of 30 pituitary genes resident within the liver cells.

Current Methods Employed to Express Proteins Using Recombinant DNA Technology

With the knowledge that specific DNA regulatory 35 sequences are required to activate gene transcription within a particular cell type, scientists have expressed foreign genes within a particular cell type through genetic

- 3 -

engineering. In general, DNA regulatory segments that are recognized by the cell's nuclear proteins are placed upstream from the coding region of a foreign gene to be expressed. In this way, after insertion into the cell, 5 foreign DNA may be expressed since the cell's nuclear regulatory proteins now recognize these DNA regulatory sequences. This technology has been employed to produce proteins that have been difficult to obtain or purify from natural sources by traditional purification strategies.

10 In addition to the recognizable DNA sequences and the gene of interest, a selectable marker is attached to the DNA construction. In this way, only the cells that have taken up the DNA survive following culture in a selectable medium. For example, the gene for neomycin 15 resistance may be included in the expression vector. Following transfection, cells are cultured in G418, a neomycin antibiotic that is lethal to mammalian cells. If however, the cells have acquired the neomycin resistance gene, they will be able to withstand the toxic effects of 20 the drug. In this way, only the cells that have taken up the transfected DNA are maintained in culture. It is understood that any selectable marker could be used as long as it provided for selection of cells that had taken up the transfected DNA. It is further understood that there is no 25 criticality as to the specific location of the inserted genetic material within the cell. It is only important that it be taken up somewhere within the nucleus as both the regulatory segment and the foreign gene (as well as the selectable marker) are inserted together.

30

Deficiencies in the Current Methods of Gene Expression

While the above techniques have been instrumental in exploiting the power of genetic engineering, they have not always been the most efficient methods to express 35 genes. This is due to the fact that insertion of DNA into the nucleus of a cell line is usually accomplished through a technique known as transfection. DNA that has been

- 4 -

engineered for expression in the cell line of interest is precipitated and the cell membrane is solubilized to allow entry of the DNA. As indicated above, the exact site into which the DNA incorporates into the genome is never 5 predictable; indeed the DNA may remain episomal (not integrated into the genome). This results in the unpredictability of both the level of expression of the protein produced and the stability of the cell line.

A second shortcoming of this technique is the 10 fact that the construction of the expression vector is extremely difficult when the gene of interest is relatively large (greater than 5-10 kilobases). Many of the proteins expressed by recombinant DNA technology have been encoded by cDNAs rather than much larger genomic clones. This is 15 done to reduce the overall size of the insert. While the use of cDNAs makes genetic engineering more convenient, rates of gene transcription and protein production may suffer as a result. It has recently been shown that expression levels are sometimes greatly enhanced through 20 the use of genomic rather than cDNA inserts (Brinster et al., Proc. Natl. Acad. Sci., 85:836-840, 1988, and Chung and Perry, Mol. Cell. Biol., 9:2075- 2082, 1989). Although the mechanisms responsible for this observation 25 are not well understood, it is known that in certain situations enhancer elements present within introns can improve the transcriptional efficiency of the gene. There is also evidence that introns, or the splicing events which result from the presence of introns, may have an effect on the RNA processing events which follow the initiation of 30 transcription (Buchman and Berg, Mol. Cell. Biol., 8:4395-4405, 1988). This may stabilize the transcript thereby improving the rate of mRNA accumulation. In the above cited Brinster et al paper, it is also postulated that the 35 position of the introns within the gene may be important for phasing of nucleosomes relative to the promoter. The influence of various regulatory elements on transcription of eukaryotic genes is discussed in Khoury et al, Cell,

- 5 -

33:313-14 (1983), Maniatis et al, Science, 236:1237-45 (1987) and Muller et al, Eur. J. Biochem., 176:485-95 (1988).

Thirdly, to gain entry into the nucleus, the 5 transfected DNA, including the entire coding region of the foreign gene, must traverse the cytoplasm following entry through the permeabilized plasma membrane of the cell. During that time, the DNA may come in contact with 10 lysosomal enzymes which may alter or completely destroy the integrity of the DNA. Thus, the coding region of the DNA 15 may not be identical to that which was transfected.

The novel method of gene activation and/or expression modification that we describe below cannot 15 result in the production of mutant forms of the desired protein, since the coding region of the desired gene is not subjected to enzymatic modifications.

In summary, a large amount of the DNA transfected 20 into the cell using traditional techniques, and particularly the coding region thereof, will not be faithfully transcribed. It may be degraded prior to entry 25 into the nucleus, enzymatically perturbed so that it will not encode the entire desired protein or it may not contain all of the necessary regulatory segments to allow for transcription. It may be inserted into a portion of the genome that prevents transcription. If the cDNA is transcribed, the protein of interest may not be produced 30 efficiently due to the omission of introns which may contain enhancers or enable efficient mRNA processing. Finally, it may remain episomal, promote protein production but be unstable as the cell population grows through cell division.

It would be most desirable to develop a method of 35 induction of gene expression that would produce a cell line that has incorporated the positive attributes of the existing methods but somehow circumvents the unattractive features. It would further be desirable to be able to express or modify endogenous expression of particular genes

- 6 -

in the cell type of choice. It is further desired to be able to take advantage of the potential benefits that may be afforded by a complete genomic sequence which may include cryptic transcriptional enhancers that may reside 5 within introns, by appropriate placement of introns for proper nucleosome phasing or by more efficient mRNA processing events. These advantages are ordinarily not enjoyed in recombinant DNA expression methods due to the size of the gene. If one were able to express a gene that 10 is already resident in the genome, i.e., an endogenous gene, cell line stability and expression rates would become more consistent and predictable.

SUMMARY OF THE INVENTION

15 Accordingly, it is an object of the present invention to eliminate the above-noted deficiencies in the prior art.

20 It is another object of the present invention to provide a method of regulation and/or amplification of gene expression that incorporates the positive attributes of recombinant gene technology but circumvents the unattractive features.

25 It is a further object of the present invention to provide a method for expressing specific genes present but normally transcriptionally silent in a cell line of choice.

30 It is yet a further object of the present invention to provide a method for expressing proteins which takes full advantage of complete genomic sequences that are responsible for mRNA accumulation and/or transcription.

35 It is still another object of the present invention to provide a method of modifying the expression characteristics of a gene of interest by inserting DNA regulatory segments and/or amplifying segments into the

- 7 -

genome of a stable cell line or cloned microorganism upstream of, within, or otherwise proximal to the native gene of interest.

It is still a further object of the present invention to provide a method for modifying the expression characteristics of a gene which is naturally present within the genome of a stable cell line or cloned microorganism and at the same time insert characteristics which will aid in the selection of cells which have been properly modified.

It is yet another object of the present invention to provide a genome having therein, proximal to the coding region or exons of a gene of interest, a regulatory or amplifying segment which does not naturally appear thereat.

It is another object of the present invention to provide DNA constructs which can be used for accomplishing the homologous recombination methods of the present invention.

It is a further object of the present invention to provide cell lines and microorganisms which include the genomes in accordance with the present invention.

These and other objects of the present invention are accomplished by means of the technique of homologous recombination, by which one of ordinary skill in this art can cause the expression and, preferably, amplification of resident, albeit transcriptionally silent genes. By this technique, one can also modify the expression characteristics of a gene which is naturally present, but not necessarily silent or inert, within the genome of a stable cell line, such as, for example, to make the expression conditional, i.e., repressible or inducible, or to enhance the rate of expression.

The present invention provides a method of modifying the expression characteristics of a gene within the genome of a cell line or microorganism. A DNA construct is inserted into that genome by the technique of

homologous recombination. The construct includes a DNA regulatory segment capable of modifying the expression characteristics of any gene to which it is operatively linked within the host cell line or microorganism, as well 5 as a targeting segment homologous to a region of the genome at which it is desired for the DNA regulatory segment to be inserted. The construct and insertion technique is designed to cause the new DNA regulatory segment to be operatively linked to the gene of interest. Thus, without 10 necessarily inserting any new coding exons, the expression characteristics of that gene are modified. In the preferred embodiment, the gene is one which is normally transcriptionally silent or inert within the host cell line or microorganism and, by means of the DNA regulatory 15 region, which is targeted directly to the appropriate position with respect to that gene by means of homologous recombination, that gene is thereby activated for expression of its gene product.

The DNA construct preferably includes two 20 targeting segments which, while separated from one another in the construct by those elements to be inserted into the genome, are preferably contiguous in the native gene.

The construct further preferably includes at 25 least one expressible selectable marker gene, such as the gene providing neomycin resistance. This marker gene, including a promoter therefor, is also disposed between the two targeting regions of the construct.

In another embodiment, the construct includes an expressible amplifiable gene in order to amplify expression 30 of the gene of interest. This gene, including a promoter therefor, is also disposed between the two targeting regions of the construct. In some cases the selectable marker and the amplifiable marker may be the same.

In a further embodiment of the present invention, 35 the DNA construct includes a negative selectable marker gene which is not expressed in cells in which the DNA construct is properly inserted. This negative selectable

- 9 -

marker gen is disposed outside of the two targeting regions so as to be removed when the construct is properly combined into the gene by homologous recombination. An example of such a negative selectable marker gene is the

5 Herpes Simplex Virus thymidine kinase gene.

In yet a further embodiment, it is possible to modify the expression characteristics of a specific gene which already expresses a product in the cell line or microorganism of interest. This can be accomplished by

10 inserting by homologous recombination a DNA construct which includes (1) an expressible amplifiable gene which increases the copy number of the gene of interest when the cell line or microorganism is subjected to amplification conditions and/or (2) a promoter/enhancer element (or other

15 regulatory element) which modifies the expression of the gene of interest such as, for example, by increasing the rate of transcription, increasing translation efficiency, increasing mRNA accumulation, making the expression inducible, etc. The gene expression which is modified in

20 this manner may be natural expression or expression which has been caused by previous genetic manipulation of the cell line or microorganism. The previous genetic manipulation may have been by conventional techniques or by means of homologous recombination in accordance with the

25 present invention. In the latter case, the DNA insertion which results in the modification of expression characteristics may be accomplished as part of the same genetic manipulation which results in expression of the gene or may be performed as a subsequent step.

30 The present invention also includes the constructs prepared in accordance with the above discussion as well as the genomes which have been properly subjected to homologous recombination by means of such constructs and the cell lines and microorganisms including these genomes.

- 10 -

Moreover, a process for preparation of the desired product by culturing the transformed cells according to the present invention is also included.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a general outline of a DNA construct in accordance with the present invention.

10 Fig. 2A shows the mode of integration of the DNA construct into the genome in the event of non-homologous or random recombination.

Fig. 2B shows the mode of integration of the DNA construct in the genome in the event of homologous recombination.

15 Fig. 3 shows the construction of a preferred homologous recombination vector in accordance with the present invention.

Fig. 4 shows the mode of integration of a circular piece of DNA by homologous recombination when only a single targeting piece of DNA is employed.

20 Fig. 5 shows the pRSVCAT plasmid, including the restriction sites thereof.

Fig. 6 shows the construction of the pRSV plasmid, including the restriction sites thereof.

25 Fig. 7 shows the pSV2NEO plasmid, including the restriction sites thereof.

Fig. 8 shows the construction of the pSVNEOBAM plasmid, including the restriction sites thereof.

Fig. 9 shows the construction of the pRSVNEO plasmid, including the restriction sites thereof.

30 Fig. 10 shows the construction of the pRSVCATNEO plasmid, including the restriction sites thereof.

Fig. 11 shows a 15.3 kb fragment of the rat TSH β gene and showing various restriction segments thereof.

35 Fig. 12 shows the construction of the pRSVCATNEOTSHB3 plasmid, including the restriction sites thereof.

- 11 -

Fig. 13 shows the construction of the pRSVCATNEOTSHB3-5XbaI plasmid, including the restriction sites thereof.

5 Fig. 14 shows a portion of the nucleotide sequence of TSHB along with the regions thereof to which each primer for PCR amplification corresponds. Exons 2 and 3 are shown in capital letters. A 247 BP amplified fragment is shown by underlined asterisks.

10 Fig. 15 shows the results of polyacrylamide gel electrophoresis of cDNA synthesized from RNA extracted from various cell populations and whose TSHB cDNA, if present, has been amplified by PCR. The nature of the cells representing the various lanes is set forth in Fig. 15 below the gel.

15

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Homologous recombination is a technique developed within the past few years for targeting genes to induce or correct mutations in transcriptionally active genes (Kucherlapati, Prog. in Nucl. Acid Res. and Mol. Biol., 36:301 (1989)). This technique of homologous recombination was developed as a method for introduction of specific mutations into specific regions of the mammalian genome (Thomas et al., Cell, 44:419-428, 1986; Thomas and 20 Capecchi, Cell, 51:503-512, 1987; Doetschman et al., Proc. Natl. Acad. Sci., 85:8583-8587, 1988) or to correct specific mutations within defective genes (Doetschman et al., Nature, 330:576-578, 1987).

30 Through this technique, a piece of DNA that one desires to be inserted into the genome can be directed to a specific region of the gene of interest by attaching it to "targeting DNA". "Targeting DNA" is DNA that is complementary (homologous) to a region of the genomic DNA. If two homologous pieces of single stranded DNA (i.e., the 35 targeting DNA and the genomic DNA) are in close proximity,

- 12 -

they will hybridize to form a double stranded helix.

Attached to the targeting DNA is the DNA sequence that one desires to insert into the genome.

There are a number of methods by which homologous 5 recombination can occur. One example is during the process of replication of DNA during mitosis in cells.

Through a mechanism that is not completely understood, parental double-stranded DNA is opened immediately prior to cell division at a local region called 10 the replication bubble. The two separated strands of DNA may now serve as templates from which new strands of DNA are synthesized. One arm of the replication fork has the DNA code in the 5' to 3' direction, which is the appropriate orientation from which the enzyme DNA 15 polymerase can "read". This enzyme attaches to the 5' portion of the single stranded DNA and using the strand as a template, begins to synthesize the complementary DNA strand. The other parental strand of DNA is encoded in the 3' to 5' direction. It cannot be read in this direction by 20 DNA polymerase. For this strand of DNA to replicate, a special mechanism must occur.

A specialized enzyme, RNA primase, attaches itself to the 3' to 5' strand of DNA and synthesizes a short RNA primer at intervals along the strand. Using 25 these RNA segments as primers, the DNA polymerase now attaches to the primed DNA and synthesizes a complementary piece of DNA in the 5' to 3' direction. These pieces of newly synthesized DNA are called Okazaki fragments. The RNA primers that were responsible for starting the entire 30 reaction are removed by the exonuclease function of the DNA polymerase and replaced with DNA. This phenomenon continues until the polymerase reaches an unprimed stretch of DNA, where the local synthetic process stops. Thus, 35 although the complementary parental strand is synthesized overall in the 3' to 5' direction, it is actually produced

- 13 -

by "backstitching" in the 5' to 3' direction. Any nicks that might occur in the DNA during the "backstitching" process are sealed by an enzyme called DNA ligase.

To maintain an absolute fidelity of the DNA code, 5 a proofreading function is present within the DNA polymerase. The DNA polymerase requires primed pieces of DNA upon which to synthesize a new strand of DNA. As mentioned above, this can be a single strand of DNA primed with RNA, or a complementary strand of DNA. When the DNA 10 polymerase finds mismatched complementary pieces of DNA, it can act as an exonuclease and remove DNA bases in a 3' to 5' direction until it reaches perfect matching again.

With this background, it is now possible to understand the basis of the technique described herein. 15 Small pieces of targeting DNA that are complementary to a specific region of the genome are put in contact with the parental strand during the DNA replication process. It is a general property of DNA that has been inserted into a cell to hybridize and therefore recombine with other pieces 20 of DNA through shared homologous regions. If this complementary strand is attached to an oligonucleotide that contains a mutation or a different sequence of DNA, it too is incorporated into the newly synthesized strand as a result of the recombination. As a result of the proof- 25 reading function, it is possible for the new sequence of DNA to serve as the template. Thus, the transfected DNA is incorporated into the genome.

If the sequence of a particular gene is known, a piece of DNA that is complementary to a selected region of 30 the gene can be synthesized or otherwise obtained, such as by appropriate restriction of the native DNA at specific recognition sites bounding the region of interest. This piece will act as a targeting device upon insertion into the cell and will hybridize to its homologous region within 35 the genome. If this hybridization occurs during DNA replication, this piece of DNA, and any additional sequence

- 14 -

attached thereto, will act as an Okazaki fragment and will be backstitched into the newly synthesized daughter strand of DNA.

In the technique of the present invention, 5 attached to these pieces of targeting DNA are regions of DNA that are known to interact with the nuclear regulatory proteins present within the cell and, optionally, amplifiable and selectable DNA markers. Thus, the expression of specific proteins may be achieved not by 10 transfection of DNA that encodes the gene itself and marker DNA, as is most common, but rather by the use of targeting DNA (regions of homology with the endogenous gene of interest) coupled with DNA regulatory segments that provide the gene with recognizable signals for transcription. With 15 this technology, it is possible to express and to amplify any cognate gene present within a cell type without actually transfecting that gene. In addition, the expression of this gene is controlled by the entire genomic DNA rather than portions of the gene or the cDNA, thus 20 improving the rate of transcription and efficiency of mRNA processing. Furthermore, the expression characteristics of any cognate gene present within a cell type can be modified by appropriate insertion of DNA regulatory segments and without inserting entire coding portions of the gene of 25 interest.

In accordance with these aspects of the instant invention there are provided new methods for expressing normally transcriptionally silent genes of interest, or for modifying the expression of endogenously expressing genes 30 of interest, within a differentiated cell line. The cognate genomic sequences that are desired to be expressed, or to have their expression modified, will be provided with the necessary cell specific DNA sequences (regulatory and/or amplification segments) to direct or modify 35 expression of the gene within the cell. The resulting DNA will comprise the DNA sequence coding for the desired

- 15 -

protein directly linked in an operative way to heterologous (for the cognate DNA sequence) regulatory and/or amplification segments. A positive selectable marker is optionally included within the construction to facilitate 5 the screening of resultant cells. The use of the neomycin resistance gene is preferred, although any selectable marker may be employed. Negative selectable markers may, optionally, also be employed. For instance, the Herpes Simplex Virus thymidine kinase (HSVtk) gene may be used as 10 a marker to select against randomly integrated vector DNA. The fused DNAs, or existing expressing DNAs, can be amplified if the targeting DNA is linked to an amplifiable marker.

15 Therefore, in accordance with the method of the present invention, any gene which is normally expressed when present in its specific eukaryotic cell line, particularly a differentiated cell line, can be forced to expression in a cell line not specific for it wherein the gene is in a silent format. This occurs without actually 20 inserting the full DNA sequence for that gene. In addition, that gene, or a normally expressing gene, can be amplified for enhanced expression rates. Furthermore, the expression characteristics of genes not totally transcriptionally silent can be modified as can the 25 expression characteristics of genes in microorganisms.

In one embodiment of the present invention, eukaryotic cells that contain but do not normally transcribe a specific gene of interest are induced to do so by the technique described herein. The homologous 30 recombination vector described below is inserted into a clonal cell line and, following chemical selection, is monitored for production of a specific gene product by any appropriate means, such as, for example, by detection of mRNA transcribed from the newly activated gene, 35 immunological detection of the specific gene product, or functional assay for the specific gene product.

The general outline of the DNA construct that is used to transcriptionally activate endogenous genes by homologous recombination is depicted in Figure 1.

In general, the DNA construct comprises at least 5 two and up to six or more separate DNA segments. The segments consist of at least one, preferably two, DNA targeting segments (A and B) homologous to a region of the cell genome within or proximal to the gene desired to be expressed, a positive selection gene (C), an amplifiable 10 gene (D), a negative selection gene (E) and a DNA regulatory segment (F) which is transcriptionally active in the cell to be transfected. In the most basic embodiment of the present invention, only a single targeting segment (B) and the regulatory segment (F) must be present. All of 15 the other regions are optional and produce preferred constructs.

Regions A and B are DNA sequences which are homologous to regions of the endogenous gene of interest which is to be made transcriptionally active. The specific 20 regions A and B of the endogenous gene are selected so as to be upstream and downstream, respectively, of the specific position at which it is desired for the regulatory segment to be inserted. Although these regions are separated in the construct they are preferably contiguous 25 in the endogenous gene. There may be occasions where non-contiguous portions of the genome are utilized as targeting segments, for example, where it is desired to delete a portion of the genome, such as a negative regulatory element.

30 While two targeting regions, A and B, are preferred in order to increase the total regions of homology and thus increase recombination efficiency, the process of the present invention also comprehends the use of only a single targeting region. In its simplest form 35 (when only the regulatory segment F and the selectable marker gene C and promoter C' are to be inserted), a circular piece of DNA is employed which contains these

- 17 -

elements along with the targeting DNA (see Figure 4). In this way, the homologous region (B) hybridizes with its genomic counterpart. Segments C', C and F are inserted within the B portion of the cognate gene following the 5 crossover event.

When it is desired for the DNA regulatory sequence to be inserted upstream of the gene of interest, as, for example, when it is desired to activate and express a normally transcriptionally silent gene, the region of 10 homology is preferably homologous to a non-coding portion of the genome upstream of the coding portions of the gene of interest. When two targeting regions are present, the downstream region (A) may include a portion of the coding region, although it is preferred that it, too, be totally 15 upstream of the coding region. It is further preferred that the homologous regions be chosen such that the DNA regulatory sequence will be inserted downstream of the native promoter for the gene of interest, particularly if the native promoter is a negative promoter rather than a 20 turned-off positive promoter.

The size of the targeting regions, i.e., the regions of homology, is not critical, although the shorter the regions the less likely that they will find the appropriate regions of homology and recombine at the 25 desired spot. Thus, the shorter the regions of homology, the less efficient is the homologous recombination, i.e., the smaller the percentage of successfully recombined clones. It has been suggested that the minimum requirement for sequence homology is 25 base pairs (Ayares et al, PNAS, USA, 83:5199-5203, 1986). Furthermore, if any of the other 30 elements of the construct are also found in the genome of the host cell, there is a possibility of recombination at the wrong place. However, in view of the excellent positive and negative selectability of the present 35 invention, it can be successfully practiced even if the efficiency is low. The ptimum results are achieved when the total region of homology, including both targeting

regions, is large, for example one to three kilobases. As long as the regulatable segment F can be operatively linked to the gene of interest there is no limit to the size of the targeting region, and particularly the upstream 5 targeting region B.

It can easily be empirically determined whether or not the targeting regions are too large or the regulatable segment F spaced too far from the coding region of the gene to be operatively linked thereto. In such a 10 case, the regions A and B can be made homologous to a different section of the gene of interest and the process repeated until the regulatable segment F is properly inserted so as to be operatively linked to the gene of interest. For example, the restriction site of combined 15 region A-B of the endogenous gene can be changed and the process repeated. Once the concept of the present invention is known, along with the techniques disclosed herein, one of ordinary skill in this art would be able to make and use the present invention with respect to any 20 given gene of interest in any cell line or microorganism without use of undue experimentation.

Region C is a positive selectable marker gene which is capable of rendering the transfected cell line 25 resistant to a normally toxic environment. Examples of such genes are adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (tk), xanthine-guanine phosphoribosyltransferase (gpt), 30 multiple drug resistance gene (MDR), ornithine decarboxylase (ODC) and N-(phosphonacetyl)-L-aspartate resistance (CAD).

In addition to the positive selectable marker gene, an amplifiable gene is also optionally included in the construct at region D. Amplifiable genes are genes 35 that lead to an increase in copy number when under selective pressure. The copy number of a gene positioned adjacent to the amplifiable gene will also increase.

- 19 -

Amplifiable genes that can be utilized include DHFR, MDR, ODC, ADA and CAD. The members of the positive selectable marker gene group and those of the amplifiable gene group overlap so that, in theory, instead of using two genes, one 5 for positive selection and one for amplification, one gene could be used for both purposes. However, since most cell lines contain endogenous copies of these amplifiable genes, the cells will already be somewhat resistant to the selection conditions and distinguishing the cells which 10 have transfected DNA from those which do not receive transfected DNA can be difficult. Thus, in instances where an amplifiable gene is desired, a positive selection gene which is dominant, such as HPH, gpt, neo and tk (in tk- cells), should also be included in the construct. For some 15 applications it may be possible or preferable to omit the amplifiable marker. For instance, the gene of interest may not need to be amplified as, for example, when transcriptional activation by the heterologous DNA regulatory sequence is sufficient without amplification. 20 Also, if the homologous recombination efficiency is very low, it may be necessary to leave out the amplifiable gene since the ratio of non-homologous DNA to homologous DNA is directly related to the homologous recombination efficiency (Letsou, *Genetics*, 117:759-770, 1987). It is also possible 25 to eliminate the positive selection gene and select cells solely by screening for the production of the desired protein or mRNA. However, it is preferred in most cases to include at least the positive selection gene.

Region E of the construct is a negative 30 selectable marker gene. Such a gene is not expressed in cells in which the DNA construct is properly inserted by homologous recombination, but is expressed in cells in which the DNA construct is inserted improperly, such as by random integration. One such gene is the Herpes Simplex 35 Virus thymidine kinase gene (HSVtk). The HSVtk has a lower stringency for nucleotides and is able to phosphorylate

- 20 -

nucleotide analogs that normal mammalian cells are unable to phosphorylate. If the HSVtk is present in the cells, nucleotide analogs such as acyclovir and gancyclovir are phosphorylated and incorporated into the DNA of the host 5 cell thus killing the cell. The presence of the negative selectable marker gene enables one to use the positive-negative selection for homologous recombination as described by Mansour et al (Nature, 336:348-352, 1988). Capecchi uses a strategy which takes advantage of the 10 differing modes of integration that occur when linearized vector DNA inserts via homologous recombination as compared to when it inserts by random integration. If the vector DNA inserts randomly, the majority of the inserts will insert via the ends (Folger et al, Mol. Cell. Biol., 15 2:1372-1387, 1982; Roth et al, Mol. Cell. Biol., 5:2599-2607, 1985; and Thomas et al, Cell, 44:419-428, 1986). On the other hand, if the vector inserts by homologous recombination, it will recombine through the regions of 20 homology which cause the loss of sequences outside of those regions.

Using the construct depicted in Figure 1 as an example, the mode of integration for homologous recombination versus random integration is illustrated in Figures 2A and 2B. In the case of non-homologous 25 recombination (Figure 2A), the vector is inserted via the ends of the construct. This allows region E, in this case the HSVtk gene, to be inserted into the genome. However, when homologous recombination occurs (Figure 2B), the HSVtk gene is lost. The first round of selection uses the 30 appropriate drug or conditions for the positive selection present within the construct. Cells which have DNA integrated either by homologous recombination or random integration will survive this round of selection. The surviving cells are then exposed to a drug such as 35 gancyclovir which will kill all the cells that contain the HSVtk gene. In this case, most of the cells in which the vector integrated via a random insertion contain the HSVtk

- 21 -

gene and are killed by the drug while those in which the vector integrated by homologous recombination have lost the HSVtk gene and survive. This allows the elimination of most of the cells which contain randomly integrated DNA,
5 leaving the majority of the surviving cells containing DNA which integrated via homologous recombination. This greatly facilitates identification of the correct recombination event.

10 The negative selection step can also be eliminated if necessary. It will require that the screening step be more labor intensive involving the need for techniques such as polymerase chain reaction (PCR) or immunological screening.

15 The sixth region (F) contains the DNA regulatory segment that will be used to make the gene of interest transcriptionally active. The appropriate DNA regulatory segment is selected depending upon the cell type to be used. The regulatory segment preferably used is one which is known to promote expression of a given gene in
20 differentiated host cell line. For example, if the host cell line consists of pituitary cells which naturally express proteins such as growth hormone and prolactin, the promoter for either of these genes can be used as DNA regulatory element F. When inserted in accordance with the
25 present invention, the regulatory segment will be operatively linked to the normally transcriptionally silent gene of interest and will stimulate the transcription and/or expression of that gene in the host cell line. Also usable are promiscuous DNA regulatory segments that work
30 across cell types, such as the rous sarcoma virus (RSV) promoter. As long as the regulatory segment stimulates transcription and/or expression, or can be induced to stimulate transcription and/or expression, of the gene of interest after being inserted into the host cell line so as
35 to be operatively linked to the gene of interest by means of the present invention, it can be used in the present invention. It is important when joining the regulatory

- 22 -

segment F to the targeting segment A that no starting codon be accidentally introduced into the sequence since such an occurrence could alter the reading frame of the gene which is desired to be expressed. Of course, the construct must 5 be constructed and inserted such that the regulatory segment F is operatively linked to the gene of interest.

The DNA regulatory segment, region F, need not be present in instances where it is desired to enhance or amplify the transcription of a gene which is already 10 expressing in the cell line of interest, either because it naturally expresses in that cell line or because the cell line has previously had its DNA manipulated to cause such expression. In such instances, insertion of an amplifiable gene, region D, preferably with the positive selectable 15 marker gene, region C, and optionally also with a negative selectable marker gene, region E, will be sufficient to increase the copy number of the gene of interest and thus enhance the overall amount of transcription.

Alternatively, a new regulatory segment, region F, 20 inherently promoting an increased (or otherwise modified) rate of transcription as compared to the existing regulatory region for the gene of interest, may be included to further enhance the transcription of the existing expressing gene of interest. Such a new regulatory segment 25 could include promoters or enhancers which improve transcription efficiency.

Regions C', D' and E' are promoter regions which are used to drive the genes in regions C, D, and E, respectively. These promoters are transcriptionally active 30 in the cell line chosen and may be the same or different from the promoter in region F used to drive the endogenous gene of interest. The specific direction of transcription specified in Fig. 1 is not critical. Those of ordinary skill in this art can determine any appropriate placement 35 of the genes C, D and E and their promoters C', D' and E' such that the promoters will stimulate expression of their

- 23 -

associated genes without simultaneously disrupting in any way the expression of the gene of interest or any of the other genes of the construct.

The present invention may be illustrated by reference to the activation of the rat thyrotropin beta subunit (TSH β) in GH₁ (ATCC CCL 82), GH₃ (ATCC CCL 82.1) or GH₄Cl cell lines (GH). GH cell lines are derived from a radiation induced pituitary tumor in rats designated MtT/W5 (Takemoto, Cancer Res., 22:917, 1962) and adapted to grow in culture by Tashjian et al, Endocrinology, 82:342-352, 1968. These cell lines may be subcloned and screened for their ability to produce growth hormone and TSH β . Such screening may preferably be by means of Northern blot analysis to determine whether mRNA for the rat growth hormone gene is present and to establish that there is no mRNA for the TSH β gene being produced. The cell lines may also be screened by Southern analysis to determine that there is at least one copy of the TSH β gene present within the genome. Only the GH cell lines that produce growth hormone and not TSH β , but contain a copy of the TSH β gene, are used.

The specific homologous recombination vector for use in GH cells may be designed in the following manner (Figure 3). Region A may consist of the 5' upstream untranslated region of the TSH β gene defined by the HindIII fragment which stretches from -74 to -2785 and region B may contain the DNA fragment that stretches from the -2785 HindIII site to a NcoI site approximately 2.1 kb further upstream as described by Carr et al (J. Biol. Chem., 262:981-987, 1987) and Croyle et al (DNA, 5:299-304, 1986). The positive selection gene (region C) may be a 1067 bp BglII-SmaI fragment derived from the plasmid pSV2neo (ATCC No. 37,149) (Southern et al, J. Mol. Appl. Gen., 1:327-341, 1982). The neo gene may be driven by the Rous Sarcoma Virus (RSV) promoter (region C') which is derived from the NdeI-HindIII fragment from the plasmid pRSVcat (ATCC No. 37,152) (Gorman et al, PNAS, 79:6777-6781,

1982). In this example, no amplifiable marker need be used and thus there need be no region D in order to optimize the efficiency of the homologous recombination. The efficiency is inversely related to the proportion of 5 non-homologous to homologous sequences present in the construct (Letsou et al, Genetics, 117:759-770, 1987). Region E, or the negative selection gene, may consist of the HSVtk gene which is a 2 kb Xho fragment obtained from the plasmid pMCITK plasmid (Capecchi et al, Nature, 10 336:348-352, 1988). The HSVtk gene in that construct may be driven by the polyoma virus promoter and enhancer (region E') as constructed by Thomas et al (Cell, 51:503- 512, 1987). In a second DNA construct the polyoma promoter may be replaced by the RSV promoter described above. The 15 DNA regulatory sequence used to activate the TSH β gene may be either the RSV promoter or the rat growth hormone promoter. The rat growth hormone promoter consists of the SacI-EcoRI fragment obtained from the plasmid pRGH237CAT (Larson et al, PNAS, 83:8283-8287, 1986). The RSV promoter 20 has the advantage of being usable in other cell lines besides GH cells, while the GH promoter is known to be active in GH cells and can be specifically induced (Brent et al, J. Biol. Chem., 264:178- 182, 1989). The rat growth hormone promoter and the RSV promoter may be inserted at 25 location F in separate constructs.

Following transfection of the above construct into a GH cell line, the cells may be grown in media that contains G418. This will allow only those cells which have 30 integrated plasmid DNA into the genome either by homologous recombination or random integration to grow. The surviving cells may be grown in media that contains gancyclovir. The majority of the cells that survive this round of selection will be those in which the vector plasmid DNA is integrated via homologous recombination. These cells may be screened 35 to demonstrate that they are producing mRNA which corresponds to the TSH β gene and that they are producing the TSH β protein. The genomic DNA may also be sequenced

- 25 -

around the area of insertion of the heterologous promoter to insure that the proper recombination event occurred.

EXAMPLE - Activation of TSH β Gene in Rat Pituitary Cells

5 Using the following protocol, thyrotropin beta subunit (TSH β) gene transcription, which normally does not occur in the rat GH $_3$ pituitary cell line, was activated in those cells by using the process of homologous recombination to target an activating element upstream of 10 the TSH β coding region. The Rous Sarcoma Virus (RSV) promoter is known to function efficiently in GH $_3$ cells (Christian Nelson et al, Nature, 322:557-562 (1986); Zheng-Sheng Ye et al, The Journal of Biological Chemistry, 263:7821-7829 (1988)) and therefore was chosen as the 15 activating element. A plasmid vector was constructed which contained the RSV activating element, portions of the 5' flanking region of the TSH β gene locus, and a selectable drug marker, aminoglycoside phosphotransferase gene (NEO), for the isolation of transfected cell populations.

20 Ribonucleic acid (RNA) was extracted from pooled drug resistant GH $_3$ cell populations and converted to complementary deoxyribonucleic acid (cDNA). The cDNA was then screened by the technique of polymerase chain reaction (PCR) for the presence of TSH β cDNA. The construction of 25 the homologous recombination vectors and the control vectors is outlined below along with the experimental procedures and results.

PLASMID CONSTRUCTION

30 Homologous Recombination (HR) Backbone Vector (pRSVCATNEO).

35 The Rous Sarcoma Virus (RSV) promoter was derived from the plasmid pRSVCAT (Cornelia M. Gorman et al., Proceedings of the National Academy of Science, 79:6777-6781 (1982)) (figure 5) by isolating the 580 base pair (bp) NdeI - HindIII fragment containing the functional promoter

unit. The ends of this fragment were blunted using DNA polymerase I Klenow fragment and XbaI linkers ligated to the blunt ends. After digestion with XbaI restriction endonuclease and gel purification, the resulting fragment 5 was ligated into the XbaI site of pUC18. A bacterial colony harboring a plasmid with the RSV insert in the orientation shown in figure 6 was designated pRSV. The aminoglycoside phosphotransferase gene (NEO) was cloned from pSV2NEO (P.J. Southern et al., Journal of Molecular
10 and Applied Genetics, 1:327-341 (1982)) by isolating the BglII and BamHI fragment (figure 7) and ligating that fragment into the BamHI site of pRSV (figure 6). A plasmid containing the NEO gene in the orientation shown in figure 8 was picked and designated pRSVNEOBAM. pRSVNEOBAM
15 was digested with SmaI and the 4328 bp fragment containing the RSV promoter region, the majority of the NEO gene and pUC18 was isolated by gel electrophoresis. The SmaI ends of this fragment were XhoI linkerized, cleaved with XhoI restriction enzyme and the plasmid recircularized by
20 ligation. The resulting plasmid is shown in figure 9 and is called pRSVNEO. This last cloning step resulted in the deletion of a 786 bp fragment from the 3' end of the NEO fragment which is not necessary for its functional expression. This construction yields a plasmid in which
25 the NEO gene is transcriptionally driven by the RSV promoter.

Next the NdeI site located 5' of the RSV promoter in pRSVCAT (figure 5) was converted to a SalI site. This was accomplished by digesting pRSVCAT with NdeI, filling in 30 the ends using DNA polymerase I Klenow fragment and ligating SalI linkers to the resulting blunt ends. The linkers were digested to completion with SalI and the plasmid recircularized by ligation. Into the newly constructed SalI site was cloned the SalI - XhoI fragment from pRSVNEO (figure 9) containing the RSV promoter and the NEO gene. A plasmid with the RSV promoter and NEO fragment oriented as shown in figure 10 was isolated and named
35

- 27 -

pRSVCATNEO. This plasmid when transfected into GH₃ cells was capable of conferring G418 resistance to those cells, demonstrating the ability of the RSV promoter to drive transcription of the NEO gene and the ability of that RNA to be translated into a functional protein (data not shown). Total RNA from the stable transfectants above was analyzed by polymerase chain reaction (PCR) to determine whether the CAT gene was being transcribed. PCR results showed that the CAT gene was indeed being transcribed in all the G418 resistant colonies tested (data not shown), indicating that the RSV promoter 5' of the CAT gene was capable of driving transcription of a gene located 3' to it. This is important because this RSV promoter will be responsible for driving transcription of the TSH β gene when the TSH β HR vector described below integrates via homologous recombination into the GH₃ genome.

TSH β HR Vector

A vector capable of integrating into the GH₃ genome by homologous recombination was created by inserting two stretches of the 5' flanking regions of the thyrotropin beta subunit (TSH β) gene into the unique SalI and HindIII sites contained in pRSVCATNEO (figure 10). A rat spleen genomic library containing inserts of 15 kilobases (kb) or greater cloned into lambda DASH was obtained from Stratagene, San Diego, CA. Using standard protocols (Current Protocols in Molecular Biology, pp.1.9.1 - 1.13.6, 6.1.1 - 6.4.10) a 15.3 kb clone of the rat genomic TSH β gene including 9kb of sequence 5' of the first exon was isolated. The 15.3 kb fragment consisted of two XbaI fragments, a 10.6 kb fragment corresponding to the 5' end of the 15.3 kb fragment and a 4.7 kb piece corresponding to the 3' region of the 15.3 kb fragment (figure 11). Both of these XbaI fragments were subcloned into pUC18 and plasmids containing inserts in both orientations were isolated. The 2.3 kb XbaI - HindIII fragment contained in the 4.7 kb XbaI fragment (figure 11) was purified and the XbaI site of this

- 28 -

fragment was converted to a HindIII site by filling in the ends with Klenow fragment and ligating on HindIII linkers. This fragment was ligated into the unique HindIII site contained in pRSVCATNEO (figure 10). An isolate 5 corresponding to a plasmid with the 2.3 kb insert in the correct orientation as shown in figure 12 was assigned the name pRSVCATNEOTSHB3.

The subcloned 10.6 kb XbaI fragment from the rat TSHB clone (figure 11) was isolated and the XbaI ends 10 converted to SalI sites by blunt ending the fragment with DNA polymerase I Klenow fragment and attaching SalI linkers. This 10.6 kb SalI fragment was then cloned into the SalI site of pRSVCATNEOTSHB3 (figure 12). A plasmid containing the insert in the correct orientation was 15 identified and named pRSVCATNEOTSHB3-5XbaI (figure 13). The latter plasmid has been deposited in the American Type Culture Collection, Rockville, MD, and has received depository number ATCC 40933. For the purpose of this 20 deposit, the plasmid was renamed pHRTSH. This deposit was made in accordance with all of the requirements of the Budapest Treaty.

CELL LINE

GH₃ cells are a subcloned population of MtT/W5 25 which was derived from a radiation induced pituitary tumor in rats (B.K. Takemoto, Cancer Research, 22:917 (1962)) and adapted to growth in culture by Tashjian et al., Endocrinology, 82:342-352 (1968). The GH₃ cells were obtained from the American Type Culture Collection cell 30 bank and are maintained in culture by growth in Dulbecco's Modified Eagle's Medium (DMEM) + 15% horse serum (HS) + 2.5% fetal bovine serum (FBS) + 1% L-glutamine (GH₃ media) at 37°C in 5% CO₂.

DNA PREPARATION

Large-Scale Preparation of Plasmid DNA

All plasmids used for stable transfections were purified by using the alkaline lysis method for large-scale 5 plasmid DNA purification as described in Current Protocols in Molecular Biology, vol. 1, pp. 1.7.1 - 1.7.2. DNA isolated by the alkaline lysis method was further purified by double banding in a cesium chloride gradient as also described in Current Protocols in Molecular Biology, vol. 10, pp. 1.7.5 - 1.7.7.

Prior to transfection, the HR vectors were digested with either AatII or ApaI. ApaI was used to linearize the control plasmid pRSVCATNEO and AatII to linearize the HR plasmid pRSVCATNEOTSHB3-5XbaI. The 15 location of the cleavage sites of ApaI and AatII can be seen in figures 10 and 13 respectively. After digestion with the appropriate restriction enzyme, the reaction was phenol/chloroform extracted, chloroform extracted, ethanol precipitated, and washed once with 70% ethanol. The 20 plasmids were then resuspended in sterile deionized water (dH₂O) to a concentration of 1 microgram/microliter (μg/μl) as determined by absorbance at OD₂₆₀. In an attempt to increase the transfection efficiency and/or the ratio of homologous recombination positives to those that were due 25 to random integration, pRSVCATNEOTSHB3-5XbaI was digested with ApaI. Digestion with ApaI cuts at three separate sites in pRSVCATNEOTSHB3-5XbaI and removes all regions of the vector except those necessary for homologous recombination (figure 13). After digestion with ApaI, the 30 reaction was electrophoresed on a 0.8% agarose gel and the top band corresponding to the 10,992 bp fragment containing the two 5' flanking regions of the TSHB gene, the RSV promoter - NEO region and the TSHB gene-activating RSV promoter was isolated from the gel by electroelution into 35 dialysis tubing. The electroeluted DNA was further purified by using an elutip minicolumn (Schleicher and Schuell) with the manufacturer's recommended standard

- 30 -

protocol. The DNA was eluted from the column, ethanol precipitated, washed with 70% ethanol and resuspended to a concentration of 1 μ g/ μ l.

5 **STABLE TRANSFECTIONS**

Calcium Phosphate Transfection

48 hours prior to transfection 3×10^6 GH₃ cells were plated on 10 centimeter (cm) dishes. For each dish, 10 μ g of vector DNA along with 30 μ g of sonicated salmon sperm DNA was added to 0.5 milliliters (ml) of tranfection buffer. The transfection buffer was prepared by combining 4g NaCl, 0.185g Kcl, 0.05g Na₂HPO₄, 0.5g dextrose, 2.5g HEPES and dH₂O to a final volume of 500 ml and bringing the pH to 7.5. 31 μ l of 2 molar (M) CaCl₂ was added to the 0.5 ml of DNA + transfection buffer and vortexed. This solution was allowed to stand at room temperature for 45 minutes. When the DNA - CaCl₂ - transfection buffer was ready, the GH₃ medium was removed from the GH₃ cells and the DNA - CaCl₂ - transfection buffer was layered over the cells. The cells were allowed to stand at room temperature for 20 minutes. After 20 minutes, 5 ml of GH₃ medium was added and the plates were incubated at 37°C for 6 hours. The cells were then shocked by aspirating off the medium and adding 5 ml of fresh transfection buffer containing 15% glycerol for 3.5 minutes. The cells were rinsed 2x with PBS and fed with 10 ml of GH₃ medium. 48 hours post-transfection, the medium was removed and 10 ml of GH₃ medium containing 400 μ g/ml G418 was added.

30 Electroporation

Electroporation was carried out using a BTX 300 Transfector with 3.5 millimeter (mm) gap electrodes. 1×10^7 GH₃ cells growing in log phase were removed from their plates by trypsinization, pelleted by centrifugation and washed once with PBS. Cells were resuspended in 1.0 ml of PBS and transferred to 2.9 ml Ultra-UV disposable cuvettes (American Scientific Products) on ice. 10 μ g of DNA was

- 31 -

added to the cells, mixed and placed back on ice for 5 minutes. After 5 minutes the electrodes were placed in the chamber and the cells were electroporated at a setting of 750 microfarads with a 200 volt pulse. The cuvette was 5 then returned to ice for 10 minutes. Cells were transferred from the cuvette to 9 ml of GH₃ medium containing 1% penicillin and 1% streptomycin at room temperature in a 15 ml conical tube and allowed to stand for 10 minutes. The total electroporation of 1 x 10⁷ cells 10 was transferred to three 10 cm plates giving approximately 3 x 10⁶ cells per plate. After 48 hours, the GH₃ medium containing 400 µg/ml G418 was added.

15 Transfection of GH₃ cells with pRSVCATNEOTSHB3-5XbaI (AatII cut), pRSVCATNEOTSHB3-5XbaI (ApaI cut) and pRSVCATNEO (ApaI cut)

pRSVCATNEOTSHB3-5XbaI (AatII cut), pRSVCATNEOTSHB3-5XbaI (ApaI cut) and pRSVCATNEO (ApaI cut) plasmids were transfected into GH₃ cells along with a no DNA control using both the calcium phosphate protocol and the electroporation protocol. 48 hours after transfection, 20 the cells were put under G418 selection. Approximately 14 to 21 days later the colonies became visible by eye on the 10 cm dishes and were counted. In all of the no DNA controls, there were no visible colonies, demonstrating that the G418 selection was working and that the presence 25 of a plasmid containing the RSV - NEO region was necessary to confer G418 resistance. At this time, colonies were picked and pooled by isolating regions on the 10 cm dish with 17 millimeter wide cloning rings. These large cloning 30 rings encompassed between 10 and 70 colonies depending on the density of the colonies per plate and allowed the GH₃ cells in that isolated region to be removed and pooled at the same time by trypsinization. The trypsinized colonies in each ring were transferred to 6 well plates and allowed to 35 grow in GH₃ media containing G418. After reaching 70% to 80% confluence, 80,000 cells were transferred to a 24 well

plate and the remaining cells cryopreserved for further testing at a later date. The cells in the 24 well plates were grown until they reached 50% to 80% confluence. Total RNA was then harvested from these GH₃ cells by the 5 following procedure.

RNA ISOLATION FROM TRANSFECTED GH₃ CELLS GROWN IN 24 WELL PLATES

The following is a modification of the protocol 10 described by Chomczynski and Sacchi, Anal. Biochem., 162:156-159 (1987). The media covering the GH₃ cells in the 24 well plates was removed and the cells washed with 1 ml of PBS. 1 ml of GTC solution was added and the cells were incubated at room temperature for 5 minutes. GTC 15 solution was prepared by dissolving 250 g of guanidium thiocyanate (Fluka) in 293 ml of dH₂O, and then adding 17.6 ml of 0.75 M Na citrate pH 7.0 and 26.4 ml of 10% sarcosyl (L-Lauryl sarcosine). Just prior to use, 360 μ l of β -mercaptoethanol per 50 ml GTC solution was added. 20 After 5 minutes at room temperature, the 1 ml of GTC-cell lysate was transferred to a Sarstedt 55.518 snap-cap tube containing 2 ml of GTC solution. To each tube was added 300 μ l of 2M sodium acetate pH 4.0 and the tube vortexed. Next, 3 ml of dH₂O saturated phenol was added and the tubes 25 were vortexed again. To each tube was added 600 μ l of chloroform:isoamyl alcohol (49:1) and the tube was shaken by hand for 10 seconds and placed on ice for 15 minutes. The tubes were then centrifuged in a Sorval RC-5B using a SM24 rotor at 8000 revolutions per minute (RPM) for 20 30 minutes at 4°C. The aqueous phase was transferred to a fresh Sarstedt tube containing 3 ml of isopropanol and placed at -20°C for 1 hour. After 1 hour the tubes were spun in a Sorval RC-5B using a SM24 rotor at 8000 rpm for 20 minutes at 4°C. The supernatants were removed and the 35 pellets resuspended in 500 μ l of GTC solution. The resuspended RNA was transferred to a 1.5 ml eppendorf tube to which 500 μ l of isopropanol was added. The tubes were

- 33 -

once again placed at -20°C for 1 hour. The eppendorf tubes were spun for 5 minutes in a microfuge and the supernatant discarded. The pellet was washed with 70% ethanol 2 times and allowed to dry until the ethanol had completely 5 evaporated. The pellet was resuspended in 20 μ l of diethyl pyrocarbonate (depc) treated water and heated to 65°C for 5 minutes. This RNA was then used to make cDNA in one of the two procedures described below.

10 cDNA REACTIONS

Method 1

First strand cDNA was synthesized from 2.5-6.0 microliters of total RNA (approximately 0.5-6 micrograms) in a reaction volume of 10-20 microliters. The total RNA 15 was obtained by the extraction method described above, and was denatured for 5-10 minutes at 70°C and quick chilled on ice before adding the reaction components. The reaction conditions were 50 millimolar (mM) Tris-HCl (pH 8.3), 10 mM MgCl₂, 10 mM DTT, 0.5 mM each of dCTP, dATP, dGTP, and dTTP 20 (Pharmacia), 40 mM KCl, 500 units/ml RNasin (Promega Biotech), 85 μ g/ml oligo(dT)₁₂₋₁₈ (Collaborative Research, Inc.), and 15,000-20,000 units/ml Moloney murine leukemia virus reverse transcriptase (Bethesda Research Laboratories) incubated at 37°C for 60 minutes. The 25 reaction was terminated by the addition of EDTA to 40 mM, and the nucleic acid was precipitated by adding sodium acetate to a concentration of 0.3 M and two volumes of ethanol. The precipitate was allowed to form at 0°C for 30 minutes and was pelleted by centrifugation in a microfuge 30 at 14,000 rpm for thirty minutes. The pellet was washed with 70% ethanol, dried, and resuspended in depc treated water to a volume of 15-25 microliters.

Method 2

35 Conditions for first strand synthesis of cDNA from RNA were adapted from Carol A. Brenner et al, BioTechniques, Vol. 7, No. 10, pp. 1096-1103 (1989). 1 μ l

- 34 -

of total RNA from the RNA prep procedure described above was added to 9 μ l of reaction buffer in a 0.5 ml eppendorf tube. The reaction buffer consisted of 200 units of Moloney murine leukemia virus reverse transcriptase (MMLVRT 5 Bethesda Research Labs), and a final concentration of the following reagents: 70 mM Tris.HCl pH 8.8, 40 mM KCl, 0.1% Triton X-100, 1 mM of each dNTP, 4 mM MgCl₂, and 0.45 OD₂₆₀ units of random hexamers (Pharmacia). After mixing, the tubes were incubated at room temperature for 10 minutes and 10 then placed at 42°C for 1 hour. After 1 hour the tubes were heated to 90°C for 1 minute to deactivate the MMLVRT and then cooled to room temperature.

15 POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION OF RNA FROM GH₃ CELLS

The following primers were used to amplify, by PCR, TSH β cDNA synthesized from RNA transcripts produced by the GH₃ cells as a result of the HR plasmids activating the endogenous TSH β gene by homologous recombination.

20	primer	5'	3'
	TSH β 5	AGTATATGATGTACGTGGACAGG	
	TSH β 3	CACTTGCCACACTTGCAGCTCAGG	

25 Figure 14 shows the regions of the TSH β gene to which each primer corresponds.

PCR REACTION CONDITIONS

All PCR reactions were performed in the Ericomp Twinblock thermocycler. If PCR amplification was to be run 30 on cDNA made by method 2, 40 μ l of additional reaction mix was directly added to the 10 μ l of the cDNA reaction bringing the total volume up to 50 μ l. The final concentrations of reagents in the 50 μ l were 70 mM Tris.HCl pH 8.8, 40 mM KCl, 0.1% Triton X- 100, 2.25 units Taq 35 polymerase (Pharmacia), 0.2 micromolar (μ M) each primer, 200 μ M each dNTP, and 0.8 mM MgCl₂.

- 35 -

If PCR was to be performed on cDNA made by method 1 above, 5 to 10 μ l of the resuspended cDNA was added to 40 to 45 μ l containing final concentrations of the following: 70 mM Tris.HCl pH 8.8, 40 mM KCl, 0.1% Triton X-100, 2.25 5 units Taq polymerase, 0.2 μ M each primer, 200 μ M each dNTP, and 0.8 mM MgCl₂.

The reactions were then subjected to the following PCR cycles.

1 minute at 94°C.
10 30 seconds at 55°C.
2 minutes at 72°C.

The above cycle was repeated 30 to 40 times. 10 μ l of each reaction mix was run on a 6% polyacrylamide gel and screened for the presence of a 247 bp PCR fragment 15 which would indicate the presence of the properly spliced mRNA for TSH β .

PCR RESULTS FOR AMPLIFICATION OF TSH β RNA FROM GH₃ CELLS AND RAT PITUITARY GLAND TOTAL RNA

20 To determine whether GH₃ cells normally synthesize TSH β RNA, cDNA from untransfected GH₃ cells as well as cDNA from rat pituitary glands was subjected to the above PCR reaction conditions. The correct 247 bp band indicative of the presence of TSH β mRNA was visible in the 25 positive control of the rat pituitary gland sample but no band was visualized from the GH₃ cell total RNA sample even after 60 cycles (data not shown).

TRANSFECTION RESULTS

30 The number of G418 resistant colonies present on the 10 cm dishes were tabulated between 14 and 21 days after addition of G418 to the media.

- 36 -

	<u>Transfection Method</u>	<u>Colonies per 10 cm dish</u>		
		<u>pRSVCATNEO</u>		<u>pRSVCATNEOTSHB3-5XBA1</u>
		<u>ApaI cut</u>	<u>Aat2 cut</u>	
5	Calcium phosphate 1	48	13	29
	Calcium phosphate 2	--	21	58
	Electroporation 1	--	1295	415
	Electroporation 2	--	1051	723

10 Total RNA was harvested from the colony pools contained in the 24 well plates as described above. cDNA was made from these RNA preps and subjected to PCR amplification. The number of positive colonies producing TSH β mRNA was determined by the presence of a 247 bp fragment as visualized on a polyacrylamide gel. Each of the pools screened contained between 10 and 70 colonies. The estimated number of colonies per pool per transfection was used to approximate the number of G418 resistant GH₃ cell clones in which TSH β gene transcription was activated.

15 20 If a pool tested positive, it was assumed that this represented one positive colony present in that particular pool.

	<u>plasmid</u>	<u>G418 resistant colonies</u>	<u>TSHβ RNA positive</u>
25	pRSVCATNEO	60	0
	pRSVCATNEOTSHB3-5XBA1 (Aat2 digested)	4942	3
	pRSVCATNEOTSHB3-5XBA1 (ApaI digested)	8580	6

30 35 These results demonstrate the successful activation of the normally transcriptionally silent TSH β gene by the method of the present invention. While the number of colonies that are positive for TSH β transcription is small compared to the number of colonies that are G418 resistant (approximately one out of every 10³ G418

- 37 -

resistant colonies), this result is generally consistent with rates reported for other homologous recombination experiments (Michael Kriegler, Gene Transfer and Expression A Laboratory Manual, Stockton Press, New York, NY (1990), 5 pp. 56 - 60). It has been generally observed that the homologous recombination rate seems to be proportional to the rate of transcription of the targeted gene (M. Frohman and G. Martin, Cell, 56:145 (1989); S. L. Mansour et al, Nature, 336:348 (1988)). It should be noted that the rate 10 which has been demonstrated is three orders of magnitude higher than what might be expected for random mutation turning on the TSH β gene.

To ensure that the results for each colony pool were reproducible and that the activation of RNA 15 transcription was stable, colony pools previously frozen away corresponding to pools which tested positive in the first screening were thawed and expanded in culture. The freshly thawed GH $_3$ positive pools were seeded in T 25 tissue culture flasks and expanded until the cells reached 20 70% to 80% confluence. 80,000 cells were then plated in 24 well plates from each flask and grown until they were 50% to 70% confluent. RNA was extracted from the cells, converted into cDNA, and screened once again for the 25 presence of TSH β RNA by running 10 μ l of each PCR reaction on a 6% polyacrylamide gel. Figure 15 shows the results of representative PCR reactions from the second screening as visualized on a polyacrylamide gel by ethidium bromide staining and fluorescence. Lanes 1, 2, and 3 contain the 30 PCR reactions run on cDNA from GH $_3$ cells which had been transfected by pRSVCATNEO. pRSVCATNEO contains no regions of homology to TSH β and thus is not capable of activating the TSH β gene by homologous recombination. As can be seen on the gel in figure 15, there are no bands corresponding to 247 bp in those lanes indicating that the TSH β gene is 35 not activated. Lane 6 also contains a negative control. In that lane three pools were combined from samples of GH $_3$ cells which had been transfected with pRSVCATNEOTSHB3-5XbaI

- 38 -

(ApaI cut) but which were negative for transcription of the TSH β gene on the first screening. The absence of the 247 bp fragment in lane 6 demonstrates that the presence of the transfected pRSVCATNEOTSHB3-5XbaI (ApaI cut) plasmid

5 integrated randomly in the genome is not capable of producing the 247 bp TSH β PCR fragment. Lanes 7, 8, 9, and 10 include PCR reactions run on cDNA made from total RNA harvested from rat pituitary glands in quantities per reaction of 25 nanograms, 100 nanograms, 200 nanograms, and 10 400 nanograms, respectively. The presence in these lanes of the expected 247 bp band, produced from cDNA prepared from a rat tissue which normally expresses TSH β , showed that the PCR reaction conditions were correctly optimized and that the PCR band obtained in lanes 4 and 5 15 containing the homologous recombination TSH β positives is of the correct size. Two pools transfected with pRSVCATNEOTSHB3-5XbaI (ApaI cut) which were positive in the first screening, ApaI-107 in lane 4 and ApaI-136 in lane 5, once again tested positive for TSH β gene activation as 20 demonstrated by the presence of the correct TSH β PCR band amplified from cDNA made from the total RNA extracts from those pools proving that transcription of TSH β gene has been stably activated. The presence of bands at 247 bp in lanes 4 and 5 containing RNA from previous positives ApaI- 25 107 and ApaI-136 and the absence of bands in the negative controls of pRSVCATNEO transfected GH₃ cells in lanes 1 - 3 and the pRSVCATNEOTSHB3-5XbaI (ApaI cut) negatives in lane 6 demonstrated that the production of TSH β RNA in a cell line that does not normally produce that RNA has been 30 stably turned on by homologous recombination.

The present invention is not limited to the cell line that is described herein. All cell lines have genetic information which is normally silent or inert. Most are able to express only certain genes. However, a normally 35

transcriptionally silent or in rt gene of any such cell line can be activated to express the gene product in accordance with the present invention and any gene of the genome may have its expression characteristics modified in accordance with the present invention. Even previously transformed cell lines can be used as long as the previous transformation did not disrupt the gene of interest. The source of the cell line is not important. The cell line may be animal or plant, primary, continuous or immortal.

5 Of course, it is desirable that any such cell line be stable and immortal so that after treatment with the technique in accordance with the present invention, expression can be commercialized. Cloned microorganisms, whether prokaryotic or eukaryotic, may also be treated by

10 15 the technique of the present invention.

While the present invention has been preferably described with respect to the expression of a normally transcriptionally silent or inert gene, the technique of the present invention is also applicable to the modification of the expression characteristics of a gene which is naturally expressed in the host cell line. For example, if it is desired to render the expression of a gene dependent upon culture conditions or the like so that expression can be turned on and off at will, an appropriate

20 25 DNA regulatory segment, such as a regulatable promoter, can be inserted which imparts such characteristics, such as repressibility or inducibility. For example, if it is known that the cell type contains nuclear steroid receptors, such as estrogen, testosterone or

30 35 glucocorticoid, or thyroxin receptors, one could use the steroid or thyroxin response elements as region F. Such a response element is any DNA which binds such receptor to elicit a positive response relative to transcription. Even if a cell is not naturally responsive to glucocorticoids, for example, a piece of DNA which encodes the glucocorticoid receptor could be added to the construct, or otherwise inserted somewhere in the genome, so as to make

- 40 -

the cell responsive to gluc corticoids. The use of a regulatable promoter could be desirable whether or not the gene of interest is normally transcriptionally silent. Other kinds of regulation can also be obtained by targeting 5 the appropriate DNA regulatory segment to the exact position of interest by means of the process of the present invention.

Thus, while stimulation of expression of normally transcriptionally silent genes is the preferred application 10 of the present invention, in its broadest sense it is applicable to the modification of expression characteristics of any gene endogenous to the host cell line.

The specific technique of homologous 15 recombination is not, per se, a novel part of the present invention. Such techniques are known and those of ordinary skill in this art will understand that any such technique can be used in the present invention as long as it permits targeting of the DNA regulatory sequence to the desired 20 location with respect to the gene of interest. While a preferred technique is disclosed, using a linearized construct with two homologous regions on either end of the sequences to be inserted, any other technique which will accomplish this function, as, for example, by using 25 circular constructs, is also intended to be comprehended by the present invention. The critical feature of the present invention is the use of homologous recombination techniques to insert a DNA regulatory sequence which causes

30

35

- 41 -

modification of expression characteristics in the cell line or microorganism being used, operatively linked with a gene in the genome of the cell line, preferably one which is normally transcriptionally silent, or to insert an 5 amplifiable sequence, without a regulatory sequence, sufficiently near a gene in the genome of the cell line which already transcribes as to cause amplification of such gene upon amplification of the amplifiable sequence. It is not absolutely necessary that a selectable marker also be 10 included. Selection can be based solely on detection of the gene product of interest or mRNAs in the media or cells following insertion of the DNA construct. Furthermore, in the embodiment in which a regulatory sequence is being inserted, amplification, while desired, is not critical for 15 operability. The same is true for the negative selection gene which makes the screening process easier, but is not critical for the success of the invention. Thus, the basic embodiment requires only insertion of the DNA regulatory segment or the amplifiable segment in the specific position 20 desired. However, the addition of positive and/or negative selectable marker genes for use in the selection technique is preferred, as is the addition of an amplifiable gene in the embodiment in which a regulatory segment is being added.

25 The term "modification of expression" as used throughout the present specification and claims, is hereby defined as excluding termination of expression by inserting by homologous recombination a mutation, deletion, stop codon, or other nucleotide sequence, including an entire 30 gene, into the gene of interest, so as to prevent the product of interest from being expressed. The prior art teaches the use of homologous recombination to insert specific mutations and the expression of a cell product may have inherently been terminated by means thereof (see, for 35 example, Schwartzberg et al, PNAS (USA), 87:3210-3214 (1990)). The present invention is not intended to encompass such a procedure. In the present invention the

- 42 -

"modification of expression" is accomplished by means of inserting regulatory and/or amplification regions at a specific desired location by means of homologous recombination. The preferred modifications are those which 5 activate and/or enhance expression of the product of interest.

Whenever the present specification uses the phrase that a DNA regulatory segment is "operatively linked with" a gene, such terminology is intended to mean that the 10 DNA regulatory segment is so disposed with respect to the gene of interest that transcription of such gene is regulated by that DNA regulatory segment. The regulatory segment is preferably upstream of the gene, but may be downstream or within the gene, provided that it operates to 15 regulate expression of the gene in some way. The DNA regulatory segment may be a promoter, terminator, operator, enhancer, silencer, attenuator, or the like, or any combination thereof.

Whenever the terms "upstream" or "downstream" are 20 used in the present specification and claims, this is intended to mean in the 5'-direction or the 3'-direction, respectively, relative to the coding strand of the gene of interest.

The foregoing description of the specific 25 embodiments so fully reveals the general nature of the invention that others can readily modify and/or adapt such specific embodiments for various applications without departing from the generic concept. Any such adaptations and modifications are intended to be embraced within the 30 meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology and terminology employed herein are for the purpose of description and not of limitation.

WHAT IS CLAIMED IS:

1. A method of activating a normally transcriptionally silent gene within the genome of a cell line or microorganism so as to enable said cell line or 5 microorganism to express the gene product of said gene, comprising inserting a DNA construct into said genome by homologous recombination, said DNA construct comprising a DNA regulatory segment capable of stimulating expression of said gene when operatively linked thereto and a DNA targeting segment homologous to a region of said genome 10 within or proximal to said gene, wherein said construct is inserted such that said regulatory segment is operatively linked to said gene of interest.
2. A method in accordance with claim 1, 21, or 15 22, wherein said DNA construct comprises two DNA targeting segments, each homologous to a region of said genome within or proximate to said gene, one of said targeting segments being upstream of said regulatory segment and the other of said targeting segments being downstream of said regulatory 20 segment.
3. A method in accordance with claim 1, 2, or 21, wherein said DNA construct additionally comprises at least one expressible selectable marker gene disposed so as to be inserted with said regulatory segment.
4. A method in accordance with claim 1, 2, 3, 25 21, 22, or 23, wherein said DNA construct additionally comprises a negative selectable marker gene disposed with respect to said targeting segment so as not to be inserted when said construct is properly inserted by homologous 30 recombination, whereby said negative selectable marker is not expressed in cells in which said DNA construct is properly inserted.
5. A method in accordance with claim 1, 2, 3, 4, or 21, wherein said DNA construct additionally comprises an 35 expressible amplifiable gene disposed so as to be inserted with said regulatory segment.

- 44 -

6. A method in accordance with claim 1, 2, 3, 4, 5, 21, 22, or 23, wherein said cell line or microorganism is a eukaryotic cell line.

5 7. A method in accordance with claim 6, wherein said cell line or microorganism is an animal cell line.

8. A method in accordance with claim 6, wherein said cell line or microorganism is a mammalian cell line.

9. A method in accordance with claim 6, wherein said cell line or microorganism is a plant cell line.

10 10. A method in accordance with claim 3, and additionally for causing expression of said gene product, further including the steps of, following said inserting step:

15 selecting clones of said cell line or microorganism which express the product of said selectable marker gene;

cultivating the selected clones under conditions sufficient to permit expression of said gene product; and collecting said gene product.

20 11. A method in accordance with claim 10, wherein said selectable marker gene is the neomycin resistance gene and said selecting step comprises selecting those clones having neomycin resistance.

25 12. A method in accordance with claim 10 or 11, wherein said DNA construct additionally comprises a negative selectable marker gene disposed with respect to said targeting segment so as not to be inserted when said construct is properly inserted by homologous recombination, whereby said negative selectable marker is not expressed in 30 cells in which said DNA construct is properly inserted, and said selecting step further includes selecting those clones which do not express said negative selectable marker gene.

35 13. A method in accordance with claim 12, wherein said negative selectable marker gene is the Herpes Simplex Virus thymidine kinase gene and said selecting step

- 45 -

includes selecting those clones which survive exposure to a media that kills cells which express said gene.

14. A genome having a DNA regulatory segment operatively linked with a naturally occurring gene at an insertion site characterized by a predetermined DNA sequence, said DNA regulatory segment not being naturally occurring at said location in the genome.

15. A cell line or microorganism capable of expressing a gene product by a normally transcriptionally silent gene within the genome of said cell line or microorganism, said genome having inserted therein a DNA regulatory segment operatively linked with said normally transcriptionally silent gene, said DNA regulatory segment being capable of promoting the expression of a gene product by said cell line or microorganism.

16. A cell line or microorganism in accordance with claim 15 or 25, wherein said DNA regulatory segment is one which is capable of promoting the expression of a gene product normally expressed by said cell line or microorganism.

17. A cell line or microorganism in accordance with claim 16, wherein the inserted DNA regulatory segment is part of a DNA construct comprising said DNA regulatory segment and at least one selectable marker gene.

18. A cell line or microorganism in accordance with claim 17, wherein said DNA construct additionally comprises an amplifiable gene.

19. A method of obtaining a gene product from a cell line or microorganism, comprising culturing a differentiated cell line or microorganism in accordance with claim 15-18 or 24-26 under conditions which permit expression of said gene product, and collecting said gene product.

- 46 -

20. A DNA construct for insertion into a predetermined host cell line or microorganism, comprising a DNA regulatory segment capable of modifying the expression characteristics of genes in the host cell line or
5 microorganism when operatively linked thereto and a DNA targeting segment homologous to a region of the genome of a preselected gene within the host cell line or microorganism.

21. A method of modifying the expression
10 characteristics of a gene within the genome of a cell line or microorganism, comprising inserting a DNA construct into said genome by homologous recombination, said DNA construct comprising a DNA regulatory segment capable of modifying the expression characteristics of said gene when
15 operatively linked thereto, as compared to its existing DNA regulatory segment, and a DNA targeting segment homologous to a region of said genome within or proximal to said gene, wherein said construct is inserted such that said regulatory segment is operatively linked to said gene of
20 interest.

22. A method of modifying the expression characteristics of a gene within the genome of a cell line or microorganism, comprising inserting a DNA construct into said genome by homologous recombination, said DNA construct comprising an expressible, amplifiable gene capable of amplifying said gene when inserted in sufficiently close proximity thereto, and a DNA targeting segment homologous to a region of said genome within or proximal to said gene, wherein said construct is inserted such that said
25 amplifiable gene is in sufficiently close proximity to said gene of interest to cause amplification thereof when said amplifiable gene is amplified.

23. A method in accordance with claim 22, wherein said DNA construct additionally comprises at least
30 one expressible selectable marker gene disposed so as to be inserted with said expressible, amplifiable gene.

- 47 -

24. A cell line or microorganism capable of enhanced expression of a gene product compared to the cell line or microorganism from which it is derived, said gene product being the expression product of an endogenous gene 5 within the genome of said cell, said genome having inserted therein in an operative manner, at or near said endogenous gene, an exogenous DNA regulatory segment and/or amplifiable gene capable of enhancing the expression of said gene product by said cell line or microorganism.

10 25. A cell line or microorganism in accordance with claim 24, wherein said exogenous DNA regulatory segment and/or amplifiable gene is an exogenous DNA regulatory segment.

15 26. A cell line or microorganism in accordance with claim 24, wherein said exogenous DNA regulatory segment and/or amplifiable gene is an exogenous amplifiable gene.

20 27. A DNA construct for insertion into a predetermined host cell line or microorganism, comprising an expressible, amplifiable gene capable of amplifying a gene in the host cell line or microorganism when inserted in sufficiently close proximity thereto, and a DNA targeting segment homologous to a region of the genome of a preselected gene within the host cell line or 25 microorganism.


28. A method in accordance with claims 1, 2, 3, 4, 5, 21, 22, or 23, wherein said cell line or microorganism is a microorganism.

30

35

1 / 14

FIG. 1




SUBSTITUTE SHEET

2/14

FIG. 2A

RANDOM INTEGRATION



RANDOM INTEGRATION






FIG. 2B

HOMOLOGOUS RECOMBINATION



HOMOLOGOUS RECOMBINATION



TRANSCRIPTION


SUBSTITUTE SHEET

3/14
F I G. 3


HOMOLOGOUS RECOMBINATION CONSTRUCT FOR RAT
TSH BETA



F I G. 4




HOMOLOGOUS RECOMBINATION



SUBSTITUTE SHEET

4/14

FIG. 5




ARROW INDICATES SENSE DIRECTION



SUBSTITUTE SHEET

5 / 14


FIG. 6



* SITE NO LONGER EXISTS
ARROW INDICATES SENSE DIRECTION

6 / 14

F I G . 7




ARROW INDICATES SENSE DIRECTION



SUBSTITUTE SHEET

7/14

FIG. 8




* SITE NO LONGER EXISTS
 ARROW INDICATES SENSE DIRECTION

SUBSTITUTE SHEET

8 / 14

FIG. 9




* SITE NO LONGER EXISTS

ARROW INDICATES SENSE DIRECTION

SUBSTITUTE SHEET

9 / 14

FIG. 10



* SITE NO LONGER EXISTS
ARROW INDICATES SENSE DIRECTION




SUBSTITUTE SHEET

10 / 14


FIG. II

RAT TSH BETA



11 / 14

FIG. 12




* SITE NO LONGER EXISTS

ARROW INDICATES SENSE DIRECTION

SUBSTITUTE SHEET

12 / 14

F / G . 13



* SITE NO LONGER EXISTS
 ARROW INDICATES SENSE DIRECTION

SUBSTITUTE SHEET

FIG. 14

13 / 14

LOCATION OF PRIMERS FOR PCR AMPLIFICATION OF TSH BETA

5'

g g c a c g c t t g a a t g t g g a a a g g a c a c t t a t g a g c t c t g t g g t c t t c c t c t g a t t t a a q C A T G A A T G C T G T C G T T C T C T T T T C C G T G C T T T C G T C T T G C T T G T G G G C A A G T G T

5' TSHB5 3' AGTATATGATGTACGTGGACAGG
CTGAGTATATGATGTACGTGGACAGGAGAGTGTGCCTAC

ACCATCTGCGCTGGGTATTGTATGACACGG gtagtttgt

gt a a t t g t a c a g g f c t a a o g t t g t c t g t t a a t t t t a g
c a t a g t c t c t c t t t g g g a a g c c a a g c a c a c t g c t t c a g a
a c a c a g a a a a a g t a c a g a t a c a t t g t a a c a g t t a c c t a
t g g t a g a t g a g a a g a a g t g t c c t t t t g t c t c t g a g g g
g t a a c a g a g c t c a g g a g t c c t t t a a g a t c a t c a g g a a c a
a t t a c a c t a a g t t g c a t g c a g t t t a t c a t g t t a a g a t c t c
CAATG GCAAACGT TCTTCCCAAGTACGCACTCTCAG

GACTTCACCTACAGAACGGTGGAAATACCGGGATGCCACA

TCCTAACCCGTTGCCCTGAGCTGCAAGTGTGGCAAGTGT

GACTCGACGTTCACACCGTTCAC
3' TSHB3 5'

ACACTGACTACAGCGACTGTAACACACGAGGCTGTCAAAACCAACTACTGCACCAAGCCA
CAGACATTCTATCTGGGGG GATTTCTGGTTAAGTGTAAATGGCAATGCAATCTGGTTAA
ATG TGT TACCTGGAATAGAACTAATAAAATATCATTGAT atgtcttgcctgc cattt
aatccataaggcacaatccacaaggcat tagagacttacacaactt tagaaqcagaggcq


EXONS 2 AND 3 ARE IN CAPITAL LETTERS

247 BP AMPLIFIED FRAGMENT UNDERLINED BY *

SUBSTITUTÉ SHEET

14 / 14

F / G . 15

DETECTION OF TSH β RNA BY PCR
AMPLIFICATION OF TOTAL RNA

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 90/07642

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: C 12 N 15/67, C 12 N 15/11, C 12 N 1/11, C 12 N 5/10

II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
IPC ⁵	C 12 N

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	WO, A, 8909256 (IMPERIAL CHEMICAL INDUSTRIES PLC) 5 October 1989 see the whole document	1
A	EP, A, 0278659 (LUBRIZOL ENTERPRISES, INC.) 17 August 1988 see the whole document	1
A	WO, A, 8805077 (MYERS, ANDREW E.) 14 July 1988 see the whole document	1
X	Gene, vol. 29, no. 1/2, June 1984, (Amsterdam, NL), O. Raibaud et al.: "A technique for integrating any DNA fragment into the chromosome of Escherichia coli", pages 231-241. see the whole article	1-3, 14-17, 19-21, 24-26, 28 /.

* Special categories of cited documents: ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

8th April 1991

Date of Mailing of this International Search Report

22.05.91

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

miss T. MORTENSEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	Gene, vol. 40, no. 1, 1985, (Amsterdam, NL), L. Janniere et al.: "Stable gene amplification in the chromosome of Bacillus subtilis", pages 47-55 see the whole article --	27
X	Gene, vol. 50, no. 1-3, 1986, (Amsterdam, NL), J. Zhu et al.: "Construction of stable laboratory and industrial yeast expressing a foreign gene by integrative transformation using a dominant selection system", pages 225-237 see the whole article	27
